| Drug Type Prophylactic vaccine | 
| Synonyms | 
| Action inhibitors | 
| Mechanism Respiratory syncytial virus F protein inhibitors, SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| COVID-19 | Preclinical | China  | 09 Feb 2024 | |
| Respiratory Syncytial Virus Infections | Preclinical | China  | 09 Feb 2024 | 





